¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement binding reaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • bimolecular reaction
    À̺ÐÀÚ¹ÝÀÀ
  • biologic false positive reaction
    »ý¹°ÇÐÀû°ÅÁþ¾ç¼º¹ÝÀÀ
  • biphasic reaction
    À̻󼺹ÝÀÀ
  • bisubstrate reaction
    µÎ±âÁú¹ÝÀÀ
  • biuret reaction
    ºä·¿¹ÝÀÀ
  • blanching reaction
    â¹é¹ÝÀÀ
  • blood transfusion reaction
    ¼öÇ÷¹ÝÀÀ
  • body-righting reaction
    ¸ö¹Ù·ÎÀâ±â¹ÝÀÀ, Á¤Çâ¹ÝÀÀ
  • cadaveric reaction
    ½Ãü¹ÝÀÀ
  • Cannizzaro¡¯s reaction
    Ä­´ÏÂ÷·Î¹ÝÀÀ
  • circular reaction
    ¼øÈ¯¹ÝÀÀ
  • color reaction
    ¹ß»ö¹ÝÀÀ, »öä¹ÝÀÀ
  • capsular precipitation reaction
    ÇǸ·Ä§Àü¹ÝÀÀ
  • capsular swelling reaction
    ÇǸ·ÆØÃ¢¹ÝÀÀ
  • carbamino reaction
    Ä«¸£¹Ù¹Ì³ë¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • anxiety reaction
    ºÒ¾È¹ÝÀÀ
  • arm tonus reaction
    À§ÆÈ±ÙÀ°±äÀå¹ÝÀÀ
  • Arthus reaction
    ¾Æ¸£Åõ½º¹ÝÀÀ
  • associated reaction
    ¿¬ÇÕ¹ÝÀÀ
  • autoimmune reaction
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • axon reaction
    Ãà»è¹ÝÀÀ
  • reaction accelerator
    ¹ÝÀÀÃËÁøÃ¼
  • bimolecular reaction
    À̺ÐÀÚ¹ÝÀÀ
  • biologic false positive reaction
    »ý¹°ÇÐÀû°ÅÁþ¾ç¼º¹ÝÀÀ
  • biotelluric reaction
    »ý¹°ÅÚ·ç·ý¿°¹ÝÀÀ
  • biphasic reaction
    À̻󼺹ÝÀÀ
  • bisubstrate reaction
    µÎ±âÁú¹ÝÀÀ
  • biuret reaction
    ºß·¿¹ÝÀÀ
  • blanching reaction
    â¹é¹ÝÀÀ
  • blood transfusion reaction
    ¼öÇ÷¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • adverse reaction
    À¯ÇØ(êóúª)¹ÝÀÀ, ¿ª(æ½)¹ÝÀÀ.
  • adverse reaction
    ºÎÀÛ¿ë
  • aerobic reaction
    È£±â¼º ¹ÝÀÀ
  • affective reaction
    Á¤µ¿¹ÝÀÀ, Á¤°¨¹ÝÀÀ
  • agglutination reaction
    ÀÀÁý¹ÝÀÀ(¡­Úãëë).
  • allergic reaction
    ¾Ë·¹¸£±â(¼º) ¹ÝÀÀ.
  • allergic reaction
    ¾Ë·¹¸£±â(¼º) ¹ÝÀÀ.
  • alternative reaction
    ±³´ë¹ÝÀÀ(ÎßÓÛÚãëë).
  • anaphylactic reaction
    ¾Æ³ªÇʶô½Ã½º¼º ¹ÝÀÀ(¡­Úãëë).
  • anaphylactic reaction
    ¾Æ³ªÇʶô½Ã¼º ¹ÝÀÀ(¡­Úãëë).
  • anaphylactic reaction
    ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀ(Úãëë),Ãʰú¹Î¹ÝÀÀ
  • anaphylactoid reaction
    ¾Æ³ªÇʶô½Ã½º¾ç ¹ÝÀÀ, °ú¹ÎÁõ¼º ¹ÝÀÀ.
  • anaphylactoid reaction
    ¾Æ³ªÇʶô½Ã¾ç ¹ÝÀÀ, °ú¹ÎÁõ¼º ¹ÝÀÀ.
  • anniversary reaction
    ±â³äÀÏ ¹ÝÀÀ
  • anorectic reaction
    ½Ä¿å°áÇ̹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • complement consumption test
    º¸Ã¼¼Òºñ½ÃÇè(¡­á¼Þ¨ãËúÐ).
  • complement deficiency
    º¸Ã¼°áÇÌ
  • complement deficient state
    º¸Ã¼°áÇÌ»óÅÂ
  • complement dependent cytotoxicity
    º¸Ã¼ÀÇÁ¸¼º ¼¼Æ÷µ¶¼º
  • complement fixation =CF
    º¸Ã¼°íÁ¤(¡­Í³ïÒ).
  • complement fixation =CF
    º¸Ã¼°áÇÕ(¡­Ì¿ùê).
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ).
  • complement fixation inhibition test
    º¸Ã¼°áÇÕÀúÇØ½ÃÇè(ÜÍô÷Ì¿ùêîÁúªãËúÐ).
  • complement fixation test
    º¸Ã¼°áÇÕ½ÃÇè
  • complement fixation test =CFT
    º¸Ã¼°íÁ¤½ÃÇè(¡­ãËúÐ).
  • complement fixation test =CFT
    º¸Ã¼°áÇÕ½ÃÇè(¡­ãËúÐ).
  • complement fixation test, indirect
    °£Á¢º¸Ã¼°áÇÕ½ÃÇè
  • complement fixation unit =CF unit
    º¸Ã¼°áÇÕ´ÜÀ§(¡­Ó¤êÈ).
  • complement fixing antibody
    º¸Ã¼°áÇÕÇ×ü(¡­ù÷ô÷).
  • complement fixing neutralization antibody
    º¸Ã¼°áÇÕ¼º ÁßÈ­Ç×ü.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • capsule swelling reaction
    ĸ½¶ ÆØÃ¢¹ÝÀÀ(ø³óìÚãëë)
  • Carr-Price reaction
    Ä«¸£-ÇÁ¶óÀ̽º ¹ÝÀÀ(Úãëë)
  • chain reaction
    ¿¬¼â¹ÝÀÀ(ææáðÚãëë)
  • chemical reaction
    È­ÇйÝÀÀ(ûùùÊÚãëë)
  • concerted reaction
    Çùµ¿¹ÝÀÀ(úðÔÒÚãëë)
  • cross-reaction
    ±³Â÷¹ÝÀÀ(Îßó©Úãëë)
  • cyanogen bromide reaction
    ºê·ÒÈ­ ½Ã¾È ¹ÝÀÀ(Úãëë)
  • cycloaddition reaction
    °í¸® ÷°¡¹ÝÀÀÈ­(ôÕÊ¥Úãëëûù)
  • dark reaction
    ¾Ï¹ÝÀÀ(äÞÚãëë)
  • diffusion-limited reaction
    È®»êÁ¦ÇÑ ¹ÝÀÀ(üªß¤ð¤ùÚÚãëë)
  • diphenylamine reaction
    ÀÌ(ì£)Æä´Ò¾Æ¹Î ¹ÝÀÀ(Úãëë)
  • Dische reaction
    µð½¬ ¹ÝÀÀ(Úãëë) (ÔÒ) diphenyulamine reaction
  • displacement reaction
    ´ëÄ¡ ¹ÝÀÀ(ÓÛöÇÚãëë)
  • disproportionation reaction
    ºÒ±Õµî¹ÝÀÀ(ÝÕгÔõÚãëë)
  • DNA polymerase chain reaction
    DNA Æú¸®¸Ó·¹À̽º ¿¬¼â ¹ÝÀÀ(ææáðÚãëë) (ÔÒ) polymerase chain reaction
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CBG capillary blood gases; coronary bypass graft; corticosteroid-binding globulin; cortisol-binding glob...
FABP fatty acid-binding protein; folate-binding protein
IBC Institutional Biosafety Committee; iodine-binding capacity; iron-binding capacity; isobutyl cyanoacr...
IBP insulin-like growth factor binding protein; International Biological Program; intra-aortic balloon p...
MBP major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
sCR1 Soluble complement receptor 1
sCR1 Soluble complement receptor type 1
TCC Terminal complement complex
APC alternative pathway of complement
C'4 complement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • explosive reaction
    Æø¹ß ¹ÝÀÀ
  • false positive reaction
    °¡¾ç¼º ¹ÝÀÀ
  • first order reaction
    ÀÏÂ÷ ¹ÝÀÀ
    ¹ÝÀÀ ¼Óµµ°¡ ¹ÝÀÀ¿¡ °ü¿©ÇÏ´Â ¹°Áú Áß ¾î´À ÇϳªÀÇ ³óµµ¿¡ ºñ·ÊÇÏ´Â ¹ÝÀÀ.
  • flora's myasthenic reaction
    Ç÷ζó ±Ù¹«·Â ¹ÝÀÀ
    ¿Ü»ó¼º ½Å°æ ¼è¾àÀÇ °æ¿ì, ±ÙÀ°¿¡ Àü±â ÀÚ±ØÀ» Àå½Ã°£¿¡ °ÉÃÄ °¡ÇÒ ¶§ º¼ ¼ö ÀÖ´Â Åן´Ï¼º ¹ÝÀÀ.
  • fright reaction
    ³î¶÷ ¹ÝÀÀ
  • heat of reaction
    ¹ÝÀÀ ¿­
  • hyperkinetic reaction
    °ú´Ù ¿îµ¿ ¹ÝÀÀ, °ú´Ù ¿îµ¿¼º ¹ÝÀÀ
  • immune reaction
    ¸é¿ª ¹ÝÀÀ
    Ç׿ø°ú Ç×ü »çÀÌÀÇ ¹ÝÀÀ.
  • inflammatory reaction
    ¿°Áõ ¹ÝÀÀ
    ¿°Áõ ÀÎÀÚ°¡ »ýü¿¡ ÀÛ¿ëÇÏ¸é »ýÃ¼Ãø¿¡´Â ¹æ¾î±â´ÉÀÌ »ý±ä´Ù. ±× ¿°Áõ¼Ò¿¡¼­ÀÇ Ç×ü³ª È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ µîÀÇ È­Çй°ÁúÀ» ÇÔÀ¯ÇÑ Ç÷Àå ¼ººÐÀ̳ª Á¶Á÷¾×ÀÇ ±¹¼ÒÀû »ïÃâ, ¹éÇ÷±¸ÀÇ Ä§À±, ȸº¹À» À§ÇÑ ¼¶À¯ Áõ»ý µîÀÇ »ýÃ¼Ãø¿¡ »ý±â´Â ¹ÝÀÀ Çö»óÀ» ¸»ÇÑ´Ù. ¿°Áõ ÀÎÀÚÀÇ Á¾·ù, ¾çÀ̳ª »ýÃ¼ÃøÀÇ »óÅ¿¡ µû¶ó¼­ ¿°Áõ ¹ÝÀÀÀÌ »ý±â´Â ¾ç»óÀº ´Ù¸£´Ù.
  • inhibition reaction
    ¾ïÁ¦, ¾ïÁ¦ ¹ÝÀÀ, ÀúÁö, ÀúÁö ¹ÝÀÀ
  • johnin reaction
    ¿ä³× º´ ¹ÝÀÀ
  • labile oxydase reaction
    ºÒ¾ÈÁ¤ ¿Á½Ã´Ù¾ÆÁ¦ ¹ÝÀÀ
  • late reaction
    Áö¿¬ ¹ÝÀÀ
  • Lecithinase reaction
    ·¹½ÃƼ³ªÁ¦ ¹ÝÀÀ
  • legal nitroprusside reaction
    ¹ý·üÀû ´ÏÆ®·ÎǪ·ç»çÀÌµå ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
RNA-binding proteins Proteins which bind to RNA molecules. Certain structure motifs are common to several of the proteins, such as arginine (arg)-rich tracts, typically consisting of alternating arg-asp, arg-ser, or arg-gly residues. These proteins also tend to have a common ribonucleotide sequence domain.
(12 Dec 1998)
guanosine triphosphate binding protein <protein> A type of protein embedded in the cytoplasmic membrane of the cell which transmits signals from outside the cell (such as from hormones binding to receptors on the outside of the cell) to the inside of the cell, where it causes some sort of biochemical reaction within the cell to the signal (such as the altering of metabolic pathways or gene expression). The process by which the protein does this is unclear but involves exchanging a molecule of GDP for a molecule of GTP.
(09 Oct 1997)
placental calcium-binding protein <protein> Calcium binding protein of placenta, uterus and vasculature containing the EF hand motif.
(18 Nov 1997)
competitive binding assay General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards.
See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay.
Synonym: displacement analysis, saturation analysis.
(05 Mar 2000)
Con A binding site <biochemistry> A common misuse of the term receptor. Con A binds to the mannose residues of many different glycoproteins and glycolipids and the binding is therefore not to a specific site.
It could be argued that the receptor is the Con A and cells have Con A ligands on their surfaces: certainly this would be less confusing.
(05 Jan 1998)
corticosteroid-binding globulin <chemical> Chemical name: Transcortins
(12 Dec 1998)
corticosteroid-binding protein <chemical> Chemical name: Transcortins
(12 Dec 1998)
progesterone-binding globulin A glycoprotein migrating as alpha 1-globulin, molecular weight 70,000 to 120,000. The protein, which is present in increased amounts in the plasma during pregnancy, binds mainly progesterone, with other steroids including testosterone competing weakly.
(12 Dec 1998)
heparin binding growth factor <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells.
Synonym: heparin binding growth factor.
Acronym: FGF
(18 Nov 1997)
protein binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
(12 Dec 1998)
serotonin-binding protein kinase <enzyme> An aspect of protein kinases EC 2.7.1.37
Registry number: EC 2.7.1.-
Synonym: sbp kinase
(26 Jun 1999)
sex hormone-binding globulin A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Changes in its concentration significantly affect the ratio of unbound (biologically active) testosterone to estradiol in plasma.
(12 Dec 1998)
sex steroid-binding globulin A protein that transports 65% of the testosterone in plasma.
Synonym: sex steroid-binding globulin.
(05 Mar 2000)
single stranded binding protein <protein> SSB's are proteins responsiblefor holding the replication fork of DNAopen while polymerases readthe templates.
(09 Oct 1997)
Nuclear actin binding protein <molecular biology> Nuclear protein, dimer of 34 kD subunits. Binds actin with Kd of around 25M.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á